12 Nov 2026, 10:27
Director Interests—
NEUNEUREN PHARMACEUTICALS LIMITED
Announcement history available from 1 August 2025
Fromto
12 Nov 2026, 10:26
Director Interests—
12 Nov 2026, 09:41
Company Administration—
5 Nov 2026, 09:57
Financial ResultsMS
2 Nov 2026, 10:37
Company UpdateMS
29 Sept 2026, 10:34
Company UpdateMS
29 Sept 2026, 09:59
Trading Halt / SuspensionMS
18 Sept 2026, 16:12
Dividends & Distributions—
2 Sept 2026, 08:50
Presentations—
26 Aug 2026, 16:56
Dividends & Distributions—
26 Aug 2026, 10:40
Financial Results—
26 Aug 2026, 09:47
Financial ResultsMS
26 Aug 2026, 09:25
Financial ResultsMS
25 Aug 2026, 08:31
Company UpdateMS
21 Aug 2026, 15:19
Presentations—
5 Aug 2026, 09:52
Company UpdateMS
24 July 2026, 09:57
Company Administration—
29 June 2026, 07:43
Company UpdateMS
18 June 2026, 16:49
Securities Administration—
1 June 2026, 17:47
Securities Administration—
1 June 2026, 17:40
Securities Administration—
27 May 2026, 16:00
Meetings & Governance—
27 May 2026, 13:22
PresentationsMS
14 May 2026, 07:30
Buybacks & Capital Management—
12 May 2026, 15:56
Company Administration—
12 May 2026, 08:34
Securities Administration—
12 May 2026, 08:32
Buybacks & Capital Management—
11 May 2026, 08:45
Buybacks & Capital Management—
7 May 2026, 09:53
Company UpdateMS
6 May 2026, 10:31
Buybacks & Capital Management—
29 Apr 2026, 08:45
Buybacks & Capital Management—
24 Apr 2026, 13:27
Meetings & Governance—
24 Apr 2026, 13:22
Meetings & Governance—
24 Apr 2026, 13:05
Company Administration—
24 Apr 2026, 12:58
Financial Results—
21 Apr 2026, 08:56
Buybacks & Capital Management—
20 Apr 2026, 08:32
Buybacks & Capital Management—
17 Apr 2026, 08:48
Buybacks & Capital Management—
10 Apr 2026, 16:55
Securities Administration—
8 Apr 2026, 09:47
Company UpdateMS
26 Mar 2026, 17:49
Securities Administration—
24 Mar 2026, 08:40
Buybacks & Capital Management—
13 Mar 2026, 08:26
Buybacks & Capital Management—
10 Mar 2026, 08:40
Buybacks & Capital Management—
6 Mar 2026, 10:25
Director Interests—
4 Mar 2026, 08:42
Buybacks & Capital Management—
3 Mar 2026, 09:50
Company UpdateMS
27 Feb 2026, 11:54
Presentations—
27 Feb 2026, 09:59
Financial ResultsMS
27 Feb 2026, 09:53
Financial ResultsMS
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 12 Nov 2026, 10:27 | Final Director's Interest Notice - P. Davies | Director Interests | — | 02010 | |
| 12 Nov 2026, 10:26 | Initial Director's Interest Notice - Zita Peach | Director Interests | — | 02008 | |
| 12 Nov 2026, 09:41 | Zita Peach to succeed Patrick Davies as Board Chair | Company Administration | — | 12017 | |
| 5 Nov 2026, 09:57 | Q3 2026 DAYBUE net sales up 39%, full year guidance upgraded | Financial Results | MS | 03021, 11001 | |
| 2 Nov 2026, 10:37 | FDA grants Orphan Drug Designation for NNZ-2591 to treat HIE | Company Update | MS | 11001 | |
| 29 Sept 2026, 10:34 | Trofinetide US patent protections extended to March 2041 | Company Update | MS | 11001 | |
| 29 Sept 2026, 09:59 | Pause in Trading | Trading Halt / Suspension | MS | 09005 | |
| 18 Sept 2026, 16:12 | Update - Dividend/Distribution - NEU | Dividends & Distributions | — | 10001, 10002, 10003 | |
| 2 Sept 2026, 08:50 | Corporate Presentation, 2 September 2026 | Presentations | — | 03026 | |
| 26 Aug 2026, 16:56 | Dividend/Distribution - NEU | Dividends & Distributions | — | 10001, 10002, 10003 | |
| 26 Aug 2026, 10:40 | Investor presentation, 26 August 2026 | Financial Results | — | 03004, 03026 | |
| 26 Aug 2026, 09:47 | Growing royalty anchors Neuren first ever dividend program | Financial Results | MS | 03004, 10001, 10002, 10003, 10006 | |
| 26 Aug 2026, 09:25 | Half Yearly Report and Accounts | Financial Results | MS | 03004, 03009, 03010, 03015, 03019, 10001, 10002, 10003 | |
| 25 Aug 2026, 08:31 | European Commission grants marketing authorisation for DAYBU | Company Update | MS | 11001 | |
| 21 Aug 2026, 15:19 | Neuren H1 2026 Financial Results Webinar on 26 August 2026 | Presentations | — | 03027, 14014 | |
| 5 Aug 2026, 09:52 | Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded | Company Update | MS | 11001 | |
| 24 July 2026, 09:57 | Neuren highlights participation in PMSF Family Conference | Company Administration | — | 12008 | |
| 29 June 2026, 07:43 | DAYBU recommended for approval in the European Union | Company Update | MS | 11001 | |
| 18 June 2026, 16:49 | Application for quotation of securities - NEU | Securities Administration | — | 06020 | |
| 1 June 2026, 17:47 | Notification of cessation of securities - NEU | Securities Administration | — | 06027 | |
| 1 June 2026, 17:40 | Notification regarding unquoted securities - NEU | Securities Administration | — | 06021 | |
| 27 May 2026, 16:00 | Results of Meeting | Meetings & Governance | — | 08003 | |
| 27 May 2026, 13:22 | AGM Chair Address & CEO Presentation | Presentations | MS | 03026, 15002 | |
| 14 May 2026, 07:30 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 12 May 2026, 15:56 | Launch of Investor Hub to enhance shareholder engagement | Company Administration | — | 12008 | |
| 12 May 2026, 08:34 | Notification of cessation of securities - NEU | Securities Administration | — | 06027 | |
| 12 May 2026, 08:32 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 11 May 2026, 08:45 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 7 May 2026, 09:53 | Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025 | Company Update | MS | 11001 | |
| 6 May 2026, 10:31 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 29 Apr 2026, 08:45 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 24 Apr 2026, 13:27 | Virtual AGM online guide | Meetings & Governance | — | 08001 | |
| 24 Apr 2026, 13:22 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004 | |
| 24 Apr 2026, 13:05 | Appendix 4G | Company Administration | — | 03025 | |
| 24 Apr 2026, 12:58 | 2025 Annual Report to shareholders | Financial Results | — | 03001, 03002, 03011, 03012 | |
| 21 Apr 2026, 08:56 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 20 Apr 2026, 08:32 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 17 Apr 2026, 08:48 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 10 Apr 2026, 16:55 | Notification of cessation of securities - NEU | Securities Administration | — | 06027 | |
| 8 Apr 2026, 09:47 | DAYBUE STIX now broadly available in US for Rett syndrome | Company Update | MS | 11001 | |
| 26 Mar 2026, 17:49 | Notification of cessation of securities - NEU | Securities Administration | — | 06027 | |
| 24 Mar 2026, 08:40 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 13 Mar 2026, 08:26 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 10 Mar 2026, 08:40 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 6 Mar 2026, 10:25 | Change of Director's Interest Notice - J Basile | Director Interests | — | 02009 | |
| 4 Mar 2026, 08:42 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 3 Mar 2026, 09:50 | Acadia confirms plan to request CHMP re-examination | Company Update | MS | 11001 | |
| 27 Feb 2026, 11:54 | Investor presentation, 27 February 2026 | Presentations | — | 03026 | |
| 27 Feb 2026, 09:59 | 2025 royalty income A$65m, profit after tax A$30m | Financial Results | MS | 03003, 03014 | |
| 27 Feb 2026, 09:53 | Appendix 4E and 2025 full year accounts | Financial Results | MS | 03003 |
1–50 of 83
1 / 2